Literature DB >> 23146908

Zipper-interacting protein kinase is involved in regulation of ubiquitination of the androgen receptor, thereby contributing to dynamic transcription complex assembly.

A Felten1, D Brinckmann, G Landsberg, K H Scheidtmann.   

Abstract

We have recently identified apoptosis-antagonizing transcription factor (AATF), tumor-susceptibility gene 101 (TSG101) and zipper-interacting protein kinase (ZIPK) as novel coactivators of the androgen receptor (AR). The mechanisms of coactivation remained obscure, however. Here we investigated the interplay and interdependence between these coactivators and the AR using the endogenous prostate specific antigen (PSA) gene as model for AR-target genes. Chromatin immunoprecipitation in combination with siRNA-mediated knockdown revealed that recruitment of AATF and ZIPK to the PSA enhancer was dependent on AR, whereas recruitment of TSG101 was dependent on AATF. Association of AR and its coactivators with the PSA enhancer or promoter occurred in cycles. Dissociation of AR-transcription complexes was due to degradation because inhibition of the proteasome system by MG132 caused accumulation of AR at enhancer/promoter elements. Moreover, inhibition of degradation strongly reduced transcription, indicating that continued and efficient transcription is based on initiation, degradation and reinitiation cycles. Interestingly, knockdown of ZIPK by siRNA had a similar effect as MG132, leading to reduced transcription but enhanced accumulation of AR at androgen-response elements. In addition, knockdown of ZIPK, as well as overexpression of a dominant-negative ZIPK mutant, diminished polyubiquitination of AR. Furthermore, ZIPK cooperated with the E3 ligase Mdm2 in AR-dependent transactivation, assembled into a single complex on chromatin and phosphorylated Mdm2 in vitro. These results suggest that ZIPK has a crucial role in regulation of ubiquitination and degradation of the AR, and hence promoter clearance and efficient transcription.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23146908     DOI: 10.1038/onc.2012.503

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin.

Authors:  Shu-Ting Chen; Maiko Okada; Ryuichiro Nakato; Kosuke Izumi; Masashige Bando; Katsuhiko Shirahige
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

Review 2.  AR-dependent phosphorylation and phospho-proteome targets in prostate cancer.

Authors:  Varadha Balaji Venkadakrishnan; Salma Ben-Salem; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

Review 3.  The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer.

Authors:  Liuxun Li; Jiangli Xu
Journal:  Clin Transl Oncol       Date:  2022-10-06       Impact factor: 3.340

4.  DAPK3 suppresses acini morphogenesis and is required for mouse development.

Authors:  Brandon A Kocher; Lynn S White; David Piwnica-Worms
Journal:  Mol Cancer Res       Date:  2014-10-10       Impact factor: 5.852

5.  Epstein-Barr Virus Enhances Cancer-Specific Aberrant Splicing of TSG101 Pre-mRNA.

Authors:  Huey-Huey Chua; Toshiki Kameyama; Akila Mayeda; Te-Huei Yeh
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 6.208

Review 6.  Posttranslational modification of the androgen receptor in prostate cancer.

Authors:  Travis van der Steen; Donald J Tindall; Haojie Huang
Journal:  Int J Mol Sci       Date:  2013-07-16       Impact factor: 5.923

7.  Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer.

Authors:  Carolina Soekmadji; James D Riches; Pamela J Russell; Jayde E Ruelcke; Stephen McPherson; Chenwei Wang; Chris M Hovens; Niall M Corcoran; Michelle M Hill; Colleen C Nelson
Journal:  Oncotarget       Date:  2016-08-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.